Evidence map›Paper›PMID 33558722›Full record

ArticleNature medicine2021

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, Alexander C Huang, Michael T Tetzlaff, Bart A van de Wiel, Serigne Lo, Ahmad A Tarhini, Elizabeth M Burton, Thomas E Pennington and 13 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06365619 (Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma), which is not on this map. Cited by 236 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
236citing papers in PubMed, 11 pooled it
31.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06365619 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

TypeinterventionalSponsorUniversity of UtahRan2026 to 2030Enrolled25ConditionsMelanomaArmsIpilimumab, Nivolumab
3 · Its place in the literature

Who cites it

236 citing papers in PubMed, 11 syntheses or guidelines pooled it, 418 citations in OpenAlex.

  1. Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.Annals of oncology : official journal of the European Society for Medical Oncology · 2026
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Neoadjuvant treatment for stage III and IV cutaneous melanoma.The Cochrane database of systematic reviews · 2023
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

176 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 4 countries.

Alexander M Menzies *Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
Rodabe N Amaria *University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6876-278X
Elisa A Rozeman *Netherlands Cancer Institute, Amsterdam, The Netherlands.
Alexander C Huang *Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-0099-0492
Michael T Tetzlaff *University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bart A van de Wiel *Netherlands Cancer Institute, Amsterdam, The Netherlands.
Serigne Lo *Melanoma Institute Australia, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0001-5092-5544
Ahmad A TarhiniH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Elizabeth M BurtonUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thomas E PenningtonMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
Robyn P M SawMelanoma Institute Australia, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-3354-806X
Xiaowei XuPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Giorgos C KarakousisPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Paolo A AsciertoIstituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Napoli, Italy.ORCID http://orcid.org/0000-0002-8322-475X
Andrew J SpillaneMelanoma Institute Australia, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-9520-0181
Alexander C J van AkkooiNetherlands Cancer Institute, Amsterdam, The Netherlands.
Michael A DaviesUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0977-0912
Tara C MitchellPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-8186-7284
Hussein A TawbiUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1942-851X
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-8991-0013
Jennifer A WargoUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3438-7576
Christian U BlankNetherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-7945-5846
Georgina V LongMelanoma Institute Australia, The University of Sydney, Sydney, Australia. georgina.long@sydney.edu.au.ORCID http://orcid.org/0000-0001-8894-3545
The University of Sydney · AUThe University of Texas MD Anderson Cancer Center · USThe Netherlands Cancer Institute · NLUniversity of Pennsylvania · USIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITMoffitt Cancer Center · USParker Institute for Cancer Immunotherapy · US

Funding

The University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL · 2019 to 2023
$10.3M
NCI NIH HHS P50 CA221703
6 · The paper itself

Abstract

The association among pathological response, recurrence-free survival (RFS) and overall survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we pooled data from six clinical trials of anti-PD-1-based immunotherapy or BRAF/MEK targeted therapy. In total, 192 patients were included; 141 received immunotherapy (104, combination of ipilimumab and nivolumab; 37, anti-PD-1 monotherapy), and 51 received targeted therapy. A pathological complete response (pCR) occurred in 40% of patients: 47% with targeted therapy and 33% with immunotherapy (43% combination and 20% monotherapy). pCR correlated with improved RFS (pCR 2-year 89% versus no pCR 50%, P < 0.001) and OS (pCR 2-year OS 95% versus no pCR 83%, P = 0.027). In patients with pCR, near pCR or partial pathological response with immunotherapy, very few relapses were seen (2-year RFS 96%), and, at this writing, no patient has died from melanoma, whereas, even with pCR from targeted therapy, the 2-year RFS was only 79%, and OS was only 91%. Pathological response should be an early surrogate endpoint for clinical trials and a new benchmark for development and approval in melanoma.

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalFemaleHumansImmunotherapyIpilimumabMaleMelanomaMiddle AgedMolecular Targeted TherapyNeoadjuvant TherapyNeoplasm Recurrence, LocalBRAF protein, humanIpilimumabNivolumabPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins B-raf

Identifiers

PMID33558722
OpenAlexW3127822472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.